Colon Cancer Data Key as Pfizer Buys Array
Acquisition could give pharma giant a first-in-class treatment for BRAF-mutant metastatic tumors.
IDH Inhibitors Target Common Mutation in Glioma
Metabolism-modulating agents shrink tumors and engage target, but some researchers worry the drugs could worsen disease.
BRAF/MEK Combo Active across Tumor Types
Dabrafenib/trametinib elicits responses, stable disease in patients with rare BRAF V600E–mutant cancers.
Going After METex14 in NSCLC
Durable responses seen with two selective MET inhibitors, capmatinib and tepotinib.
AMG 510 First to Inhibit “Undruggable” KRAS
Drug elicits responses in half of patients with NSCLC; leads to stable disease in other cancers.
Merck Buys Maker of HIF2α Inhibitor
Acquisition may boost development of hypoxia-targeting drugs for ccRCC and other tumor types.
Aiming TILs at Melanoma, Cervical Cancer
Autologous cell therapies induce durable responses in patients with relapsed/refractory disease.
Drugging OXPHOS Dependency in Cancer
Experimental complex I inhibitor IACS-010759 is safe, well tolerated; clinical activity reported in solid tumors.
Mechanism of Cediranib/Olaparib Combo Revealed
The VEGFR inhibitor confers sensitivity to the PARP inhibitor in non–BRCA-mutant ovarian cancer by interfering with DNA repair in two ways.
“Super Trastuzumab” Extends PFS in Late-Line Breast Cancer
Margetuximab prolongs progression-free survival among patients already treated for HER2-positive breast cancer.
Maintenance Olaparib New Standard in Pancreatic Cancer?
PARP inhibitor improved PFS and DoR in patients with BRCA-mutated disease.
Enzalutamide Bests Older NSAAs in mHSPC
Adding next-gen AR inhibitor to standard androgen deprivation therapy improves overall survival.
Anti-BCMA CAR T-cell Therapy Reins in Myeloma
Patients on high doses almost universally respond, with minimal neurotoxicity.
Scientists See Human Cancer in Zebrafish
With new animal model, researchers see tumor growth, drug responses—and ID potential rhabdomyosarcoma therapy.
High ORRs Seen with Tagraxofusp-erzs in BPDCN
However, the CD123-targeted therapy can cause serious side effects.
Children Successfully MATCHed to Therapies
Based on tumor sequencing, pediatric basket trial assigned more kids to targeted treatment than anticipated.